Achatz Maria Isabel, Zambetti Gerard P
Department of Oncogenetics, A.C. Camargo Cancer Center, São Paulo, SP, Brasil.
Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105.
Cold Spring Harb Perspect Med. 2016 Dec 1;6(12):a026195. doi: 10.1101/cshperspect.a026195.
A common criticism of studying rare diseases is the often-limited relevance of the findings to human health. Here, we review ∼15 years of research into an unusual germline TP53 mutation (p.R337H) that began with its detection in children with adrenocortical carcinoma (ACC), a remarkably rare childhood cancer that is associated with poor prognosis. We have come to learn that the p.R337H mutation exists at a very high frequency in Southern and Southeastern Brazil, occurring in one of 375 individuals within a total population of ∼100 million. Moreover, it has been determined that carriers of this founder mutation display variable tumor susceptibility, ranging from isolated cases of pediatric ACC to Li-Fraumeni or Li-Fraumeni-like (LFL) syndromes, thus representing a significant medical issue for this country. Studying the biochemical and molecular consequences of this mutation on p53 tumor-suppressor activity, as well as the putative additional genetic alterations that cooperate with this mutation, is advancing our understanding of how p53 functions in tumor suppression in general. These studies, which originated with a rare childhood tumor, are providing important information for guiding genetic counselors and physicians in treating their patients and are already providing clinical benefit.
对罕见病研究的一个常见批评是其研究结果对人类健康的相关性往往有限。在此,我们回顾了约15年对一种罕见的种系TP53突变(p.R337H)的研究,该研究始于在肾上腺皮质癌(ACC)患儿中检测到这种突变,肾上腺皮质癌是一种极为罕见的儿童癌症,预后较差。我们了解到,p.R337H突变在巴西南部和东南部人群中以非常高的频率存在,在约1亿总人口中,每375人就有1人携带该突变。此外,已确定这种奠基者突变的携带者表现出不同的肿瘤易感性,从个别儿童肾上腺皮质癌病例到李-弗劳梅尼综合征或李-弗劳梅尼样(LFL)综合征,因此这对该国来说是一个重大的医学问题。研究这种突变对p53肿瘤抑制活性的生化和分子影响,以及与该突变协同作用的假定其他基因改变,正在推动我们对p53一般在肿瘤抑制中如何发挥作用的理解。这些起源于一种罕见儿童肿瘤的研究,正在为指导遗传咨询师和医生治疗患者提供重要信息,并且已经带来了临床益处。